

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

Phase II OvaRex® Study Demonstrates Survival Benefit for Ovarian Cancer Patients

Silver Spring, MD and Wellesley, MA, February 3, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that Alan Gordon, MD, Director of Research in Gynecology at US Oncology, Houston, Texas, presented results of a 20-patient phase II trial of OvaRex® at the Society of Gynecologic Oncologists (SGO) meeting in New Orleans. The presentation provided results of OvaRex MAb (oregovomab) treatment in conjunction with second line chemotherapy in patients with late stage ovarian cancer.

The study demonstrated that an OvaRex-associated T cell immune response to the tumor or to CA125, a specific ovarian tumor marker, correlates with a highly favorable clinical outcome. Eleven of the eighteen patients who could be evaluated mounted a T cell response and showed significantly prolonged survival compared to non responders (median not reached versus 51.9 weeks, $p=.002$).

These results support the conclusion that OvaRex stimulates the immune system to help patients fight their disease. The findings follow the recent *NEW ENGLAND JOURNAL OF MEDICINE* publication, by Zhang et al. (NEJM Jan 16, 2003; 348:203-13) establishing association between tumor-infiltrating T cells and favorable outcomes in patients with stage III/ IV ovarian cancer. The presence of tumor-specific T cells appears to be a critically important factor in prolonging survival in ovarian cancer patients.

“We now know that there is a very strong correlation between the presence of T cells in tumors and favorable prognosis. The OvaRex study establishes an approach to induce T cells to target a tumor, from peripheral blood,” commented Dr. Gordon. “We now must initiate confirmatory studies to establish the benefit of chemotherapy in combination with OvaRex induced immune stimulation. The initial data are very promising.”

United Therapeutics recently announced the initiation of two identical pivotal Phase III clinical trials called IMPACT I and II being conducted at centers throughout the United States. OvaRex® MAb is an investigational immunotherapeutic monoclonal antibody being developed by Unither Pharmaceuticals, a wholly-owned subsidiary of United Therapeutics, for the treatment of stage III/IV advanced ovarian cancer following successful completion of front-line therapy. A list of participating sites in the IMPACT I and II trials may be obtained by accessing www.clinicaltrials.gov and entering the keyword: OvaRex.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

The statement made in this press release about initiating confirmatory studies to establish the benefit of chemotherapy in combination with OvaRex induced immune induction is a forward-looking statement that represents United Therapeutics' expectations concerning future events. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' reports on Form 10-K and Form 10-Q as filed with the Securities and Exchange Commission, which may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' reports and documents filed with the Securities and Exchange Commission. United Therapeutics undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or any other reason.

* * *